Corticotropin Releasing Factor Receptor Antagonists

What is this patent about?

’201 is related to the field of pharmaceutical compositions and methods for treating congenital adrenal hyperplasia (CAH). CAH is a genetic disorder characterized by a deficiency in enzymes involved in cortisol synthesis, leading to an overproduction of androgens. Current treatments often involve glucocorticoids, which can have significant side effects, highlighting the need for alternative or adjunctive therapies.

The underlying idea behind ’201 is to use a CRF1 receptor antagonist to modulate the hypothalamic-pituitary-adrenal (HPA) axis, thereby reducing the excessive androgen production characteristic of CAH. By blocking the CRF1 receptor, the drug aims to decrease the release of adrenocorticotropic hormone (ACTH), which stimulates the adrenal glands to produce androgens. This approach seeks to address the root cause of androgen excess in CAH, rather than just managing the symptoms.

The claims of ’201 focus on a method of treating CAH in a human by administering a therapeutically effective amount of a CRF1 receptor antagonist or a pharmaceutically acceptable salt thereof. The key feature is that the androstenedione (A4) level is reduced from baseline and maintained at a reduced level post 24 hours , indicating a sustained therapeutic effect.

In practice, the CRF1 receptor antagonist, formulated as a tablet or capsule, is administered orally. The dosage is adjusted to achieve a therapeutic effect, specifically a reduction in androstenedione levels. The treatment aims to normalize hormone levels, potentially allowing for a reduction in the dose of glucocorticoids, thus minimizing their associated side effects. The compound's long half-life allows for less frequent dosing.

’201 differentiates itself from prior approaches by targeting the CRF1 receptor, a key regulator of the HPA axis. Unlike glucocorticoids, which suppress the entire adrenal steroidogenesis pathway and can cause significant side effects, the CRF1 receptor antagonist aims to selectively reduce androgen production. This targeted approach offers the potential for improved hormonal control and reduced side effects , leading to better long-term outcomes for patients with CAH.